Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study

Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study

There are increasing efforts to better predict adverse outcomes for idiopathic pulmonary fibrosis (IPF). Our aim was to assess the prognostic potential of ischemia-modified albumin (IMA), an established circulating marker of ischemia and, more recently, oxidative stress, in a cohort of 56 IPF patien...

Full description

Bibliographic Details
Main Authors: Angelo Zinellu, Stefano Zoroddu, Simona Fois, Sabrina Mellino, Chiara Scala, Erika Virdis, Elisabetta Zinellu, Salvatore Sotgia, Panagiotis Paliogiannis, Arduino A. Mangoni, Ciriaco Carru, Pietro Pirina, Alessandro G. Fois
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Antioxidants
Subjects:
ACB test
IMA
IPF
survival
Online Access:https://www.mdpi.com/2076-3921/13/3/278

Internet

https://www.mdpi.com/2076-3921/13/3/278

Similar Items